Six weeks of GLP-1 infusion resulted in significant improvements in fasting (decrease of 4.3 mM glucose) and 8 h mean glucose (decrease of 5.5 mM), fasting and mean 8h free fatty acids, a reduction in HbA1c from 9.2% to 7.9%, a decrease in fructosamine from 349 uM to 282 uM, and a reduction in gastric emptying 3,4
This study investigates the effects of allulose, a rare sugar shown to reduce blood glucose, in a rat model of diet-induced obesity and T2D
CSD initiates the release of inflammatory mediatorsincluding ATP, glutamate, calcitonin gene-related peptide (CGRP), and nitric oxide (NO)which activate pial nociceptors and promote sustained activation of dural nociceptors
Food reduces the bioavailability of oral semaglutide by up to 40%
This guarantees reliable experimental performance across a range of applications, from mechanism-of-action studies to therapeutic development and screening of next-generation metabolic drugs
This data helps clinicians adjust dosages, detect potential side effects, and ensure the patients overall health is improving
